|
Synonyms: compound I-908 [US20190256519A1] | NDI-034858 | NDI034858 | TAK-279 | TAK279
Compound class:
Synthetic organic
Comment: NDI-034858 is an orally bioavailable TYK2-selective inhibitor. Its chemical structure was revealed during the first disclosures session at the 2022 ACS meeting in Chicago. NDI-034858 is one of the compounds (specifically I-908) claimed in patent US20190256519A1 [3]. The chemical structure is identical to that for the INN zasocitinib, and the name-to-structure was formally disclosed in 2026 [4].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
| References |
|
1. Elbuluk N, Armstrong AW, Vender R, Bhutani T, Green L, Ferris LK, Laquer V, Moore A, Weisman J, Zhang W et al.. (2026)
Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb Trial. Dermatol Ther (Heidelb), 16 (6): 3215-3234. [PMID:42143206] |
|
2. Leit S, Greenwood JR, Mondal S, Carriero S, Dahlgren M, Harriman GC, Kennedy-Smith JJ, Kapeller R, Lawson JP, Romero DL et al.. (2022)
Potent and selective TYK2-JH1 inhibitors highly efficacious in rodent model of psoriasis. Bioorg Med Chem Lett, 73: 128891. [PMID:35842205] |
|
3. Masse CE, Greenwood JR, Mondal S, Cowen SD, McLean TH. (2019)
Tyk2 inhibitors and uses thereof. Patent number: US20190256519A1. Assignee: Nimbus Discovery Inc. Priority date: 28/07/2017. Publication date: 22/08/2019. |
|
4. Mehrotra S, Sano Y, Halkowycz P, Wilson E, Durairaj C, Kong KF, Xia G, Dunbar F, Spector T, Heap GA et al.. (2026)
Pharmacological Characterization of Zasocitinib (TAK-279): An Oral, Highly Selective, and Potent Allosteric TYK2 Inhibitor. J Invest Dermatol, 146 (1): 214-222.e7. [PMID:40441292] |